Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Joanna
Joanna Albala, Stockton, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110188782 | Hand-Held Portable Microarray Reader For Biodetection - A hand-held portable microarray reader for biodetection includes a microarray reader engineered to be small enough for portable applications. The invention includes a high-powered light-emitting diode that emits excitation light, an excitation filter positioned to receive the excitation light, a slide, a slide holder assembly for positioning the slide to receive the excitation light from the excitation filter, an emission filter positioned to receive the excitation light from the slide, a lens positioned to receive the excitation light from the emission filter, and a CCD camera positioned to receive the excitation light from the lens. | 08-04-2011 |
Joanna Ashton-Chess, Nantes FR
| Patent application number | Description | Published |
|---|---|---|
| 20100104581 | Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions - The present invention relates to a method of diagnosis and/or prognosis of an inflammatory condition, which method comprises determining the expression level of TRIB1 in a biological sample of a patient, in particular in peripheral blood or in a biopsy of a diseased tissue. Methods for treating inflammatory conditions by modulating TRIB1 expression or activity are also described. | 04-29-2010 |
| 20100305038 | DIAGNOSTIC OF IMMUNE GRAFT TOLERANCE USING TMTC3 GENE EXPRESSION LEVELS - The present invention concerns a method for the in vitro diagnosis or prognosis of a graft tolerant or graft non-tolerant phenotype, comprising: determining from a grafted subject biological sample an expression profile comprising TMTC3 gene, optionally measuring other parameters, and determining the presence of a graft tolerant or graft non-tolerant phenotype from said expression profile and optional other parameters, wherein said method does not comprise determining an expression profile comprising, in addition to TMTC3, the following 7 genes: BUB1B, CDC2, CHEK1, MS4A1, RAB30, RHOH, and SYNGR3. Said method may further comprise, if said subject is diagnosed as a graft non-tolerant subject, diagnosing from the expression profile if said subject is developing chronic rejection. The present invention also relates to a medicament comprising a TMTC3 protein, or a fragment, an analogue or an analogue fragment thereof, in particular for the treatment, prevention, delay or inhibition of graft rejection. | 12-02-2010 |
| 20110071071 | PSMB10: A DIAGNOSIS MARKER AND THERAPEUTIC TARGET OF CHRONIC REJECTION - The present invention relates to a method for diagnosing chronic graft rejection of a grafted organ in a subject from a biological sample of said subject, comprising: (a) determining in vitro an expression level value for PSMB10 in said subject biological sample, (b) comparing said value to at least one reference expression level value for PSMB10 in at least one reference sample, and (c) diagnosing if said subject is or not undergoing chronic rejection of said grafted organ. The invention also concerns a diagnostic kit or microarray for performing the method of the invention. The invention further concerns the medical use of proteasome inhibitors for treating chronic rejection. | 03-24-2011 |
Joanna Bakala, Paris FR
| Patent application number | Description | Published |
|---|---|---|
| 20100129471 | ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERIZATION - The invention relates to a compound of the formula (I) in which: R | 05-27-2010 |
| 20110160228 | DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION - The present invention relates to compounds of formula (I) below in which: —R | 06-30-2011 |
Joanna Birch-Jones, Kent GB
| Patent application number | Description | Published |
|---|---|---|
| 20110318988 | TOY COMPRISING A FRUIT OR VEGETABLE SHAPED BODY AND AN AUDIO DEVICE - A toy is disclosed comprising a fruit or vegetable shaped body and an audio device configured to play a pre-recorded message, wherein the audio device is housed in a housing external to the toy and coupled to the toy. The audio device may be configured to play a pre-recorded message which recites the benefits of eating that particular fruit or vegetable. | 12-29-2011 |
Joanna Chorostowska-Wynimko, Warsaw PL
| Patent application number | Description | Published |
|---|---|---|
| 20100137209 | MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 AND METHODS BASED THEREON - The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfhydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modified PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyperfibrinolysis, hemophilia, and vessel leakage syndrome. | 06-03-2010 |
Joanna Dojillo, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110003736 | PESTICIDAL PROTEINS - The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences that encode these proteins. In preferred embodiments, these pesticidal proteins have molecular weights of approximately 40-50 kDa and of approximately 10-15 kDa. | 01-06-2011 |
Joanna Duligall, Bristol GB
| Patent application number | Description | Published |
|---|---|---|
| 20100080394 | QKD transmitter and transmission method - In order to facilitate alignment of a QKD transmitter and QKD receiver, the transmitter is provided with a retro-reflector for returning to the receiver a photon beam originating at the latter. The transmitter is arranged to polarization modulate the retro-reflected beam. The transmitter is provided both with an intensity detector for generating an indication of retro-reflected photon intensity, and an intensity-dependent controller for controlling the QKD transmitter in dependence on the detected photon intensity. In one embodiment, this control involves aborting operation of the QKD transmitter upon an unexpectedly high photon intensity being detected; in another embodiment, the intensity indication is used to control the attenuation of the retro-reflected beam so as stabilize the average retro-reflected photon count per unit time. | 04-01-2010 |
Joanna Duligall, Gloucester GB
| Patent application number | Description | Published |
|---|---|---|
| 20090310784 | QKD System Alignment - QKD receiving apparatus is provided with an alignment-correction system for correcting misalignment of a quantum signal received at an optical port of the apparatus relative to a quantum-signal detector of the receiving apparatus. The alignment-correction system comprises a misalignment measuring subsystem for making multiple different misalignment measures, and a misalignment compensation subsystem for adjusting the relative alignment of the quantum signal and quantum-signal detector in dependence on the misalignment measures made. The misalignment measuring subsystem comprises an alignment-beam source, an alignment-beam detector arrangement, and optical components for guiding an alignment beam from the alignment-beam source to the optical port, and for guiding the alignment beam, after external retro-reflection at a cooperating QKD transmitting apparatus from the optical port to the alignment-beam detector arrangement. | 12-17-2009 |
Joanna Dziewiszek, Boxborough, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110196025 | Polymorphs of N-Malonyl-Bis(N'-Methyl-N'-Thiobenzoylhydrazide) - At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition. | 08-11-2011 |
Joanna Fare, Huddinge SE
| Patent application number | Description | Published |
|---|---|---|
| 20100043970 | METHOD OF PRODUCING A WOOD BASED PRODUCT - The present invention relates to a method of producing a wood based product comprising applying a water-based adhesive composition comprising non-gelatinised starch, the composition further comprises from 0.1 to 50 weight % of one or more polymers (P) containing an amine group or an amide group, onto one or more pieces of a wood-based material and joining the one or more pieces with one or more further pieces of a wood based material. | 02-25-2010 |
Joanna Fraczek, Gent BE
| Patent application number | Description | Published |
|---|---|---|
| 20100196929 | STABILISATION OF THE PHENOTYPIC PROPERTIES OF ISOLATED PRIMARY CELLS - The invention provides a method for stabilisation of phenotypic properties of isolated primary cells comprising modulating at least two epigenetic modifications in said cells. | 08-05-2010 |
| 20100278782 | DIFFERENTIATION OF RAT LIVER EPITHELIAL CELLS INTO HEPATOCYTE-LIKE CELLS - Methods for differentiation of cells of a rat liver epithelial (RLEC) cell line to hepatocyte-like cells are disclosed. In particular, methods involve sequential exposure of the RLEC to two or more differentiation agents. Cells obtained by the method are described as well as their uses in various pharmacological, toxicological, therapeutic, diagnostic and research applications. | 11-04-2010 |
Joanna Gajewiak, Salt Lake City, UT US
| Patent application number | Description | Published |
|---|---|---|
| 20100261681 | ALPHA-CHLORO AND ALPHA-BROMO PHOSPHONATE ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF - Described herein is the synthesis and pharmacology of a series of α-substituted methylene phosphonate analogs, in which the α-CH | 10-14-2010 |
Joanna Guzzetta, Portland, OR US
| Patent application number | Description | Published |
|---|---|---|
| 20100005717 | SYSTEM AND METHOD FOR POTTING PLANTS - Embodiments of a system and method for potting plants are disclosed. The system can include a drain shield, a filling material, and a liner for placing between the filling material and a growing medium. In particular embodiments, the filling material comprises expanded polystyrene spheres. The liner is a porous material allowing passage of fluids and preventing passage of substantial amounts of growing medium. The drain shield can include a top wall, at least two supports, at least two bottom walls, and a bottom member having a plurality of openings. The drain shield may include adhesive strips for securing the drain shield to a bottom wall of the container. Also disclosed are embodiments of a method for potting a plant in a container having at least one drain hole in a bottom wall of the container. | 01-14-2010 |
Joanna Hergovich Lisztwan, Basel CH
| Patent application number | Description | Published |
|---|---|---|
| 20100125064 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases - The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula I, | 05-20-2010 |
| 20110230457 | Substituted Isoquinolinones and Quinazolinones - The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) | 09-22-2011 |
Joanna Iczkiewicz, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20090137463 | Treatment for Neurodegeneration - Polypeptides which are an N- and/or C-terminally truncated fragment of the human osteopontin (hOPN) sequence or species variant, and which minimally have a 15 amino acid sequence corresponding to amino acids 138 to 152 of hOPN, and polynucleotides encoding said polypeptide, are useful for treatment or prevention of neurodegeneration. | 05-28-2009 |
Joanna Jakobkiewicz-Banecka, Gdansk PL
| Patent application number | Description | Published |
|---|---|---|
| 20090062380 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - The invention relates to the medical use of natural isoflavones and their semisynthetic derivatives or the pharmaceutically acceptable salts thereof for the therapeutic and/or prophylactic treatment of diseases, at the base of which lies an excessive production or storage of glycosaminoglycans, especially for treatment of mucopolysaccharidoses. The isoflavones and their semisynthetic derivatives are represented by formula (I), in which R | 03-05-2009 |
Joanna Jamontt, Hatfield GB
| Patent application number | Description | Published |
|---|---|---|
| 20100286098 | USE OF TETRAHYDROCANNABINOL AND/OR CANNABIDIOL FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease. | 11-11-2010 |
Joanna Jusis, Lincoln Park, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090197952 | Glyceride Esters for the Treatment of Diseases Associated with Reduced Neuronal Metabolism of Glucose - Provided are alternative sources of ketone bodies for reducing or eliminating symptoms of Parkinson's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Alzheimer's disease, Huntington's disease, epilepsy and other diseases or disorders characterized by impaired glucose metabolism. The alternative sources of ketone bodies include mono-, di- and triglyceride esters of acetoacetate and mixtures thereof, and/or mono-, di- and triglyceride esters of 3-hydroxybutyrate and mixtures thereof. These glyceride esters can be administered orally as a dietary supplement or in a nutritional composition. | 08-06-2009 |
Joanna Keep, Stevenage GB
| Patent application number | Description | Published |
|---|---|---|
| 20110273747 | APPARATUS AND METHOD FOR FACSIMILE TRANSMISSION CONFIGURATION - An apparatus and method that configures a facsimile transmission protocol for a facsimile device is disclosed. The method can include transmitting an echo request via a network connection to a facsimile device. The method can include receiving a response to the echo request via the network connection from the facsimile device. The method can include determining network throughput impairments based on the received response to the echo request. The method can include adjusting a facsimile transmission protocol based on the determined network throughput impairments. The method can include transmitting a facsimile message based on the adjusted facsimile transmission protocol. | 11-10-2011 |
| 20110296498 | Fax authentication for secure fax transmission and of unwanted faxes - A system and a method of authenticating faxes are disclosed. The method includes receiving image data that includes at least one page to be transmitted by a sending fax device. An authentication code is generated at the sending fax device. The authentication code is transmitted to a receiving fax device. The receiving fax device determines whether the authentication code is one which is accepted. If it is, the receiving fax device authorizes commencement of the fax transmission. | 12-01-2011 |
Joanna Keep, Hertfordshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20110051713 | FACSIMILE PRIORITIZATION WITHIN INTERNET PROTOCOL CALL NETWORKS - A method and apparatus maintain a facsimile number priority hierarchy within a computer storage medium and process a first facsimile call being transmitted through a computerized call processor. The first facsimile call is made between a first telephone number associated with the computerized call processor and a second telephone number not associated with the computerized call processor. While processing the first facsimile call, the computerized call processor receives an indication of an attempt to connect a second facsimile call between the first telephone number and a third telephone number. The third telephone number is not associated with the computerized call processor. The method and apparatus determine a priority between the second telephone number and the third telephone number based on the facsimile number priority hierarchy. If the second telephone number has a higher priority than the third telephone number, the computerized call processor does not connect the second facsimile call. However, if the third telephone number has a higher priority than the second telephone number, the computerized call processor terminates the first facsimile call and connects the second facsimile call by connecting the third telephone number to the first telephone number. | 03-03-2011 |
Joanna Klein Nagel Voort, Zwolle NL
| Patent application number | Description | Published |
|---|---|---|
| 20100040814 | RESIN COMPOSITION SUITABLE FOR (RE) LINING OF TUBES, TANKS AND VESSELS - The present invention relates to structural, radically curable resin compositions suitable for (re)lining containing a. 30-70 wt. % of a resin characterized by (i) a molecular weight M | 02-18-2010 |
Joanna Kowalska, Radom PL
| Patent application number | Description | Published |
|---|---|---|
| 20100233757 | Synthesis and Use of Anti-Reverse Phosphorothioate Analogs of the Messenger RNA Cap - New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2′-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are “anti-reverse cap analogs” (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five-fold more efficiently than mRNAs synthesized with the conventional analog m | 09-16-2010 |
| 20110092574 | mRNA Cap Analogs - Dinucleotide cap analogs are disclosed, modified at different phosphate positions with a boranophosphate group or a phosphoroselenoate group. The analogs are useful as reagents in the preparation of capped mRNAs and have increased stability both in vitro and in vivo. They may be used as inhibitors of cap-dependent translation. Optionally, the boranophosphate or phosphoroselenoate group has a 2′-O or 3′-O-alkyl group, preferably a methyl group, producing analogs called BH | 04-21-2011 |
Joanna Kubler-Kielb, Bethesda, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100150954 | VACCINES AGAINST INFLUENZA VIRUS - Disclosed are immunogenic conjugates having the general formula: | 06-17-2010 |
| 20100158937 | METHODS FOR CONJUGATION OF OLIGOSACCHARIDES OR POLYSACCHARIDES TO PROTEIN CARRIERS THROUGH OXIME LINKAGES VIA 3-DEOXY-D-MANNO-OCTULSONIC ACID - Methods for preparing an oligosaccharide-protein carrier immunogenic conjugate or a polysaccharide-protein carrier immunogenic conjugate. The methods include obtaining an oligosaccharide or polysaccharide having a KDO moiety located at the terminal reducing end of the oligosaccharide or polysaccharide that includes a carbonyl functional group; and reacting the carbonyl functional group of the KDO moiety with an aminooxylated protein carrier molecule resulting in a conjugate that includes a covalent oxime bond between the oligosaccharide and the protein carrier or the polysaccharide and the protein carrier. | 06-24-2010 |
| 20100183678 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES - Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against | 07-22-2010 |
| 20100330074 | USE OF SACCHARIDES CROSS-REACTIVE WITH BACILLUS ANTHRACIS SPORE GLYCOPROTEIN AS A VACCINE AGAINST ANTHRAX - Provided are immunogenic compositions and methods for eliciting an immune response against | 12-30-2010 |
| 20110182929 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA - Disclosed are immunogenic conjugates which elicit an immune response to | 07-28-2011 |
| 20110212125 | VACCINE FOR SHIGELLA - Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an | 09-01-2011 |
| 20110223163 | MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS - The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of | 09-15-2011 |
Joanna Kubler-Kielb, Rockville, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100040644 | METHODS FOR PREPARING IMMUNOGENIC CONJUGATES - Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage. | 02-18-2010 |
| 20100062023 | CHOLESTEROL-CONTAINING COMPOUNDS AND THEIR USE AS IMMUNOGENS AGAINST BORRELIA BURGDORFERI - Unique compounds that can be used for inducing an immune response to | 03-11-2010 |
Joanna Lai, Santa Clara, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100184276 | LOW-TEMPERATURE FORMATION OF POLYCRYSTALLINE SEMICONDUCTOR FILMS VIA ENHANCED METAL-INDUCED CRYSTALLIZATION - A method for forming polycrystalline semiconductor film from amorphous semiconductor film at reduced temperatures and/or accelerated rates. The inclusion of a small percentage of semiconductor material, such as 2% within the metal layer, reduces the temperatures required for crystallization of the amorphous semiconductor by at least 50° C. in comparison to the use of the metal layer without the small percentage of semiconductor material. During a low temperature isothermal annealing process adjacent Al-2% Si and a-Si films undergo a layer exchange resulting in formation of a continuous polycrystalline silicon film having good physical and electrical properties. Formation of polycrystalline-semiconductor in this manner is suitable for use with low temperature substrates (e.g., glass, plastic) as well as with numerous integrated circuit and MEMs fabrication devices and practices. | 07-22-2010 |
Joanna Lignelli, Baltimore, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20080268987 | MOLDED LACROSSE HEAD POCKET - A pocket for a head of a lacrosse stick is provided that includes a plurality of runners extending generally in a longitudinal direction and a plurality of cross laces extending generally in a transverse direction. The pocket further includes one or more joint members that are formed at an intersection of a runner and a cross lace. The runner and the cross lace lie over one another and are held in place by the joint member. A method for forming the pocket is also disclosed. | 10-30-2008 |
Joanna Lubas, Fremont, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080269868 | STENT DELIVERY CATHETER SYSTEM AND METHOD OF IMPLANTING A SELF-EXPANDING STENT WITH EMBOLIC PROTECTION - A catheter system and method for implanting an i such as a stent at a treatment site in a patient's body lumen. The catheter provides a complete system for stent delivery, dilatation, and delivery and/or recovery of an expandable device, such as an embolic protection device, adjacent to the treatment site in the body lumen. | 10-30-2008 |
| 20100331951 | STENT DELIVERY CATHETER SYSTEM AND METHOD OF IMPLANTING A SELF-EXPANDING STENT WITH EMBOLIC PROTECTION - A catheter system and method for implanting an endoprosthesis such as a stent at a treatment site in a patient's body lumen. The catheter provides a complete system for stent delivery, dilatation, and delivery and/or recovery of an expandable device, such as an embolic protection device, adjacent to the treatment site in the body lumen. | 12-30-2010 |
Joanna Mamrowicz, Lesko PL
| Patent application number | Description | Published |
|---|---|---|
| 20110284103 | ACCESSING A VALVE ASSEMBLY OF A TURBOMACHINE - An example method of accessing a valve assembly of a turbomachine includes accessing a check valve of the valve assembly from a first position that is radially outside a flow path through the turbomachine. The method accessing a shut off valve of the valve assembly from a second position that is radially outside the flow path. The check valve and the shut off valve are configured to influence communication of lubricant along a lubricant communication path that extends between a location radially outboard the flow path and a location radially inboard the flow path. The first position is the same as the second position in some examples. | 11-24-2011 |
Joanna Matyjasik, Denatrion PL
| Patent application number | Description | Published |
|---|---|---|
| 20110105342 | METHOD FOR DETERMINING REDUCED PREDISPOSITION TO CANCER BASED ON GENETIC PROFILE - The invention provide methods for early detection of a reduced risk of developing cancer, which comprises detecting the absence of a series of genetic polymorphisms associated with a predisposition of developing cancer, including the polymorphisms of the genes BRCA1, BRCA2, CARD15 (NOD2), CHEK2, CDKN2A (P16), CYP1B1, FGFR2 (KGFR2), MAP3K1 (MEKK1), p53 (TP53), TNRC9, XPD (ERCC2) and the genetic marker Rs6983267, in a biological sample from the analyzed subject, wherein the absence of the genetic polymorphisms is indicative of significantly decreased risk of developing, at least, breast cancer. | 05-05-2011 |
Joanna Mecfel-Marczewski, Altenmarkt An Der Alz DE
| Patent application number | Description | Published |
|---|---|---|
| 20110313177 | 2-Oxo-1, 3-dioxolane-4-carboxylic Acid and Derivatives Thereof, Their Preparation and Use - 2-Oxo-1,3-dioxolane-4-carboxylic acid and derivatives thereof, according to the following formula, | 12-22-2011 |
Joanna Norstroem, Basel CH
| Patent application number | Description | Published |
|---|---|---|
| 20110160730 | Osteosynthesis Plate for Treatment of Fractures or Osteotomies in the Vicinity of Joints - The osteosynthesis plate according to the invention comprises at least two legs, which are spaced apart and interconnected by at least one bridge element. The legs each have a certain length and extend in the longitudinal direction from an epiphyseal to a diaphyseal end of the osteosynthesis plate. Moreover, both legs each comprise at least one opening for holding an anchoring element. The size and shape of the at least one bridge element and the at least two legs are configured such that the legs may be applied on both sides of a bone in the region of a joint, preferably on the olecranon. | 06-30-2011 |
Joanna Oat, Ledyard, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20110252557 | SOIL SOLIDIFIER AND RELATED METHODS - A method for constructing a structure, preferably a swimming pool, includes the steps of excavating a cavity, applying a sub-base such as sand along at least a portion of the cavity, forming the sub-base into the desired shape of the structure, and applying a solidifier solution to the sub-base. The solidifier solution comprises a polymer in solution. The solidifier solution and the sub-base harden to form a smooth, hard composite layer in the base of the cavity, with the composite layer containing at least some of the polymer and at least some of the sub-base in a polymer lattice. After the solidifier solution has been applied, a liner may be installed, and the swimming pool may be filled. | 10-20-2011 |
| 20110257314 | SOIL SOLIDIFIER AND RELATED METHODS - A method for constructing a structure, preferably a swimming pool, includes the steps of excavating a cavity, applying a sub-base such as sand along at least a portion of the cavity, forming the sub-base into the desired shape of the structure, and applying a solidifier solution to the sub-base. The solidifier solution comprises a polymer in solution. The solidifier solution and the sub-base harden to form a smooth, hard composite layer in the base of the cavity, with the composite layer containing at least some of the polymer and at least some of the sub-base in a polymer lattice. After the solidifier solution has been applied, a liner may be installed, and the swimming pool may be filled. Additionally, the solidifier solution may be applied directly to the cavity, or to masonry or other materials, and may be used to construct any applicable structure. | 10-20-2011 |
Joanna Sweetgall, Allendale, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110104017 | PORTABLE UV WATER TREATMENT SYSTEM - A portable water purification system and method of operation of the system is disclosed that may comprise a container defining a water purification chamber; a plurality of UV generating light sources distributed in the purification chamber of the container; and a portable power source electrically connected to the light sources, and adapted to convert kinetic energy to electrical energy to provide to the light sources. The portable power source may be adapted to be driven by human motive power to provide the kinetic energy. The purification system may comprise a filling opening to the container; and a filter intermediate the filling opening and the chamber adapted to remove turbidity from the water entering the water purification chamber through the filling opening. The portable power source may comprise a hand-cranked electrical generator. The UV light sources may produce UV light in a wavelength band selected to effectively deactivate all harmful biological water contaminants, and produce UV light in a dosage sufficient to effectively deactivate all harmful biological water contaminants. | 05-05-2011 |
Joanna Szpunar, Lons FR
| Patent application number | Description | Published |
|---|---|---|
| 20090014640 | Nebulizer with Nanometric Flow Rate of a Liquid Effluent and Nebulizing Installation Comprising Same - The invention concerns a nebuliser with nanometric flow rate of a liquid effluent in a nebulising gas comprising at least arranged substantially concentric, a capillary tube for intake of the liquid effluent and a nebulising needle including a central channel fed with liquid effluent through the capillary tube, a chamber for intake of the nebulising gas feeding a nozzle for expelling the nebulising gas, the nebulising needle passing through the intake chamber and the nozzle expelling the nebulising gas, the nebulising needle including a outlet for the liquid effluent whereof the aperture diameter is less than 20 ?m, the ratio of the diameter of the outlet of the nozzle expelling the nebulising gas and the outlet of the nebulising needle being more than 10 The inventive nanometric flow rate nebuliser and nebulising installation are applicable in mass spectrometry of trace elements contained in intracellular or microbiological medium for example. | 01-15-2009 |
Joanna Tobien, Glienicke/nordbahn DE
| Patent application number | Description | Published |
|---|---|---|
| 20080248486 | Type Pept1 Protein Assay - The present invention relates to a type PepT1 protein assay and in particular a process for identifying a substrate and/or a modulator of the PepT1 protein. | 10-09-2008 |
Joanna Vlahopoulou, Newcastle Upon Tyne GB
| Patent application number | Description | Published |
|---|---|---|
| 20100206079 | ULTRASONIC MONITOR FOR A BIOREACTOR - A method and apparatus for monitoring the state of a microbiological or animal cell culture, or other bioprocess wherein the attenuation and in some embodiments, the speed of an ultrasonic wave passed through the culture is used to determine viscous and viscoelastic properties of the culture medium. | 08-19-2010 |
Joanna Wencel, Cesson-Sevigne FR
| Patent application number | Description | Published |
|---|---|---|
| 20100267956 | CHIRAL TRIDENTATE COMPOUNDS, CORRESPONDING ORGANOMETAL COMPLEXES, METHOD FOR PREPARING SAME AND USE OF SAID COMPOUNDS AND COMPLEXES AS LIGANDS IN ASYMMETRICAL CATALYSIS - The invention relates to a compound of the formula (I) or the formula (II) in which: W is an oxygen atom or a radical of the formula NH; X is hydrogen or an alkaline cation or a C1-C8 alkyl or a —(CH | 10-21-2010 |
Joanna Wietrzyk, Wroclaw PL
| Patent application number | Description | Published |
|---|---|---|
| 20090264510 | Double helical oligonucleotides interfering with mRNA used as effective anticancer agents - The present invention relates to the application of double-helical oligonucleotides (siRNA) interfering with the mRNA of gene involved in carcinogenesis, particularly the Wnt1, Wnt2 or Her3 genes. Such oligonucleotides may be modified chemically, used in conjunction with viral and non-viral vectors such as lipid complexes. Such oligonucleotides exhibit unusual anti-proliferative properties against tumour cells and may be used in anti-tumour treatment. | 10-22-2009 |
| 20110245466 | METHOD OF PRODUCTION OF POLYANIONIC DRUG-CARRIER CONJUGATES - The invention concerns the method of production of a polyanionic macromolecule which is a protein built, among others, form polar amino acids (such as lysine, arginine, aspartic acid, glutamic acid), characteristic in that, that as a result of the reaction between amine groups and the cyclic anhydride of dicarboxylic acid, the charge changes towards more negatively charged carrier. This reaction gives rise to better therapeutic properties of macromolecules modified in this way. | 10-06-2011 |
Joanna Wojtalik, Victoria AU
| Patent application number | Description | Published |
|---|---|---|
| 20080308430 | Packaging for a Disposable Item - Packaging ( | 12-18-2008 |
Joanna Zagrodzka, Warszawa PL
| Patent application number | Description | Published |
|---|---|---|
| 20090105483 | PROCESS FOR THE PREPARATION OF PRAMIPEXOLE BASE AND/OR ITS SALTS - The process for the preparation of pramipexole base and/or its pharmaceutically acceptable salts, especially the hydrochloride salt, in the alkylation reaction of (S)-(−)2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with an alkylating agent, wherein the reaction is carried out in the absence of a base, and in a solvent from which the resulting N-monoalkylated product selectively precipitates out as a salt. After isolation from the reaction mixture, the N-monoalkylated product is converted a) into the free pramipexole base upon treatment with an inorganic base and is then converted into another pharmaceutically acceptable pramipexole salt; or b) directly into another pharmaceutically acceptable pramipexole salt or the hydrate thereof. | 04-23-2009 |
| 20110065922 | Process for Preparation Of Solifenacin and/or the Pharmaceutically Acceptable Salts Thereof of High Pharmaceutical Purity - A process for the preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity is characterized in that 3-(R)-quinuclidinoloxy anion generated in situ from 3-(R)-quinuclidinol in a presence of strong base in polar organic solvent is subject to acylation with (S)-1-phenyl-1,2,3,4-tetrahydroisoquinolinecarbonyl chloride of chemical purity at least 98%, while maintaining constant anion excess in a reaction mixture, and after reaction completion solifenacin base is optionally transformed into solifenacin salt according to standard procedures. (S)-1-Phenyl-1,2,3,4-tetrahydroisoquinolinecarbonyl chloride of chemical purity at least 98% is obtained in a reaction of (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline and molar excess of phosgene in a presence of tertiary aromatic amine in aromatic hydrocarbon, and isolated in a crystalline form. | 03-17-2011 |
| 20110077405 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE (S)-1-PHENYI-1,2,3,4- TETRAHYDROISOQUINOLINE - Process for preparation of (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline wherein 1-phenyl-1,2,3,4-tetrahydroisoquinoline is reacted with D-(−)-tartaric acid in a solvent system comprising of methanol and water, preferably at 3.3:1 to 1:1 volume ratio, the crystallization mixture is left for crystallization and (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline is released from obtained crystalline diastereoisomeric salt according to standard procedures. (S)-1-Phenyl-1,2,3,4-tetrahydroisoquinoline is the intermediate in enantiomeric synthesis of solifenacin. | 03-31-2011 |
Joanna Zuberek, Warsaw PL
| Patent application number | Description | Published |
|---|---|---|
| 20110092574 | mRNA Cap Analogs - Dinucleotide cap analogs are disclosed, modified at different phosphate positions with a boranophosphate group or a phosphoroselenoate group. The analogs are useful as reagents in the preparation of capped mRNAs and have increased stability both in vitro and in vivo. They may be used as inhibitors of cap-dependent translation. Optionally, the boranophosphate or phosphoroselenoate group has a 2′-O or 3′-O-alkyl group, preferably a methyl group, producing analogs called BH | 04-21-2011 |